Journal List > Perinatology > v.30(4) > 1144136

Jo, Kim, and Kim: Serious Necrotizing Enterocolitis in a Neonate Treated with Octreotide for Congenital Chylothorax

Abstract

The somatostatin analog octreotide has recently been introduced in the treatment of infants with chylothorax. The safety profile of octreotide has not been fully evaluated. Octreotide reduces the splanchnic blood flow in a dose-dependent manner, affecting the entire gastrointestinal tract. Some concern has been recently raised regarding the potential implications of this effect in the development of necrotizing enterocolitis in neonates receiving octreotide for congenital hyperinsulinism or chylothorax. To our knowledge, there is no case report linking the use of octreotide with necrotizing enterocolitis in Korea. We report a case of serious necrotizing enterocolitis in a neonate treated with octreotide for congenital idiopathic chylothorax.

Figures and Tables

Fig. 1

The initial infantogram showed massive right pleural effusion.

pn-30-249-g001
Fig. 2

Infantogram (A) and abdominal ultrasonography (B) showed the findings consistent with necrotizing enterocolitis. Notable features include generalized bowel loop distension, pneumatosis coli (A, arrow), and portal venous air (B, arrows).

pn-30-249-g002
Fig. 3

Intraoperative findings were consistent with necrotizing enterocolitis involving extensive areas of jejunum, ileum, and colon.

pn-30-249-g003
Table 1

Laboratory Data after Admission

pn-30-249-i001

Abbreviations: HD, hospital day; RBC, red blood cell; WBC, white blood cell.

Table 2

Summary of Cases of Octreotide Associated Necrotizing Enterocolitis

pn-30-249-i002

Abbreviations: IV, intravenously; HI, hyperinsulinism; SQ, subcutaneously; TC, transverse colon; SB, small bowel.

*Cases of octreotided-associated nectrotizing enterocolitis.

References

1. Valentine VG, Raffin TA. The management of chylothorax. Chest. 1992; 102:586–591.
crossref
2. Ulíbarri JI, Sanz Y, Fuentes C, Mancha A, Aramendia M, Sánchez S. Reduction of lymphorrhagia from ruptured thoracic duct by somatostatin. Lancet. 1990; 336:258.
crossref
3. Au M, Weber TR, Fleming RE. Successful use of somatostatin in a case of neonatal chylothorax. J Pediatr Surg. 2003; 38:1106–1107.
crossref
4. Yin R, Zhang R, Wang J, Yuan L, Hu L, Jiang S, et al. Effects of somatostatin/ octreotide treatment in neonates with congenital chylothorax. Medicine (Baltimore). 2017; 96:e7594.
5. Rasiah SV, Oei J, Lui K. Octreotide in the treatment of congenital chylothorax. J paediatr Child Health. 2004; 40:585–588.
crossref
6. Lam JC, Aters S, Tobias JD. Initial experience with octreotide in the pediatric population. Am J ther. 2001; 8:409–415.
crossref
7. Austin JD, Hofman P, Anderson BJ. Life-threatening hyperkalemia following partial pancreatectomy for neonatal hyperinsulinism. Pediatr Crit Care Med. 2008; 9:e17–e19.
crossref
8. Reck-Burneo CA, Parekh A, Velcek FT. Is octreotide a risk factor in necrotizing enterocolitis? J pediatr Surg. 2008; 43:1209–1210.
crossref
9. Laje P, Halaby L, Adzick NS, Stanley CA. Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism. Pediatr Diabetes. 2010; 11:142–147.
crossref
10. Hawkes CP, Adzick NS, Palladino AA, De León DD. Late presentation of fulminant necrotizing enterocolitis in a child with hyperinsulinism on octreotide therapy. Horm Res Paediatr. 2016; 86:131–136.
crossref
11. Mohseni-Bod H, Macrae D, Slavik Z. Somatostatin analog (octreotide) in management of neonatal postoperative chylothorax: is it safe? Pediatr Crit Care Med. 2004; 5:356–357.
crossref
12. Sivasli E, Dogru D, Aslan AT, Yurdakok M, Tekinalp G. Spontaneous neonatal chylothorax treated with octreotide in Turkey: a case report. J Perinatol. 2004; 24:261–262.
crossref
13. Paget-Brown A, Kattwinkel J, Rodgers BM, Michalsky MP. The use of octreotide to treat congenital chylothorax. J Pediatr Surg. 2006; 41:845–847.
crossref
14. Demirbilek H, Shah P, Arya VB, Hinchey L, Flanagan SE, Ellard S, et al. Long-term follow-up of children With congenital hyperinsulinism on octreotide therapy. J Clin Endocrinol Metab. 2014; 99:3660–3667.
crossref
15. Henry MC, Moss RL. Neonatal necrotizing enterocolitis. Semin Pediatr Surg. 2008; 17:98–109.
16. Martinez-Tallo E, Claure N, Bancalari E. Necrotizing enterocolitis in full-term or near-term infants: risk factors. Biol Neonate. 1997; 71:292–298.
crossref
17. Abbo O, Harper L, Michel JL, Ramful D, Breden A, Sauvat F. Necrotizing enterocolitis in full term neonates: is there always an underlying cause? J Neonatal Surg. 2013; 2:29.
crossref
18. Ostlie DJ, Spilde TL, St Peter SD, Sexton N, Miller KA, Sharp RJ, et al. Necrotizing enterocolitis in full-term infants. J Pediatr Surg. 2003; 38:1039–1042.
crossref
19. Martini S, Aceti A, Lima M, Maffi M, Faldella G, Corvaglia L. Octreotide in a critically ill extremely preterm infant with perforated necrotizing enterocolitis. Pediatrics. 2016; 138:e20160467.
crossref
TOOLS
Similar articles